Eurolyser Diagnostics - Premium Laboratory Equipment

PSA (prostate-specific antigen) test: A new assay for prostate cancer screening

Monday, 9. December 2019

Eurolyser presents its new medical parameter for the measurement of PSA. This test is approved by notified body under ISO 13485:2016

The parameter

Prostate specific antigen (PSA) is a glycoprotein with a molecular weight of 34,000 which is located in the prostatic organization and seminal plasma. The PSA out of the blood increases with the occurence of prostate cancer, prostatomegaly, prostatitis and other prostatic diseases. Particularly blood PSA levels increase remarkably in patients with prostate cancer.

Your advantages

  • Whole blood sample
  • Fully quantitative
  • Easy test procedure
  • Results in < 6 minutes
  • Patient-near analysis
  • Decisive results


Antibodyadsorbed latex particles and PSA in the sample react immunologically, and causing the latex particles to agglutinate. This agglutination results in a change of turbidity, and the change in absorbance is a measure of the amount of PSA in the sample.

Measurement range

Serum/plasma:          2 – 50 ng/ml (LOT pending)
EDTA whole blood:    3 – 50 ng/ml (LOT and HCT pending)

For more information, please visit the PSA test kit page

Eurolyser News

10. December 2019

Launch of bidirectional connectivity: a feature for CUBE series instruments...
»

9. December 2019

PSA (prostate-specific antigen) test: A new assay for prostate cancer screening...
»

5. December 2019

Eurolyser is now ISO 13485:2016 certified...
»

15. October 2019

Cortisol: A brand new veterinary assay for metabolism monitoring...
»